Efalizumab (Raptiva) Is Safe For Long-Term Use In Psoriasis Patients
A review of data based on ten years of experience using efalizumab (Raptiva®) to treat chronic plaque psoriasis confirms that that the drug has a favorable long-term safety profile. The chronic plaque form of psoriasis accounts for about 75 percent of psoriasis cases.
This post is an original post by ScienceDaily: Skin Care News
Posted: May 28th, 2008 under skin health.
Comments: none
Write a comment